HTG, BMS ink collaboration agreement
TUCSON, Ariz.—HTG Molecular Diagnostics Inc. and Bristol-Myers Squibb have begun a research collaboration agreement to evaluate the potential of immuno-oncology molecular profiling in multiple tumors types. Per the terms of the agreement, HTG will grant access to its next-generation sequencing (NGS)-based HTG EdgeSeq system, and both companies will collaborate on the development of tools for use in molecular profiling research in immuno-oncology. No financial details were disclosed.
“We believe this collaboration will provide many benefits to Bristol-Myers Squibb’s immuno-oncology development programs and further add to HTG’s industry leadership in the development of NGS-based molecular diagnostic assays toward the goal of precision medicine. This collaboration is the result of a long-standing Bristol-Myers Squibb/HTG relationship, and we are excited to continue as a partner with Bristol-Myers Squibb’s translational research team,” said John Lubniewski, chief business officer for HTG.